Asian Journal of Pharmacodynamics and Pharmacokinetics

Cheng TF et al. Asian Journal of Pharmacodynamics and Pharmacokinetics 2009; 9(1):27-49
Gordon AN, Markman M, McMeekin DS, Monk BJ, Rose
PG. Role of pegylated liposomal doxorubicin in ovarian
cancer. Gynecol Oncol 2005; 96(1):10-8.
33. Awesh Kumar Yadav, Pradeep Mishra, Anil K. Mishra,
Pushpa Mishra, Sanyog Jain, Govind Prasad Agrawal.
Development and characterization of hyaluronic
acid–anchored PLGA nanoparticulate carriers of
doxorubicin. Nanomed 2007; 3(4):246-257.
34. Tarl W. Prow, Imran Bhutto, Sahng Y. Kim, Rhonda
Grebe, Carol Merges, Koichi Uno, Mohamed Mennon,
Li Rodriguez, Kam Leong, Gerard A. Lutty. Ocular
nanoparticle toxicity and transfection of the retina and
retinal pigment epithelium. Nanomed 2008; 4(4):340-349.
35. Prashanth K. Jayanna, Vladimir P. Torchilin, Valery
A. Petrenko. Liposomes targeted by fusion phage proteins.
Nanomed 2009; 5(1):83-89.
36. Qinghe Zhao, Bingyun Li. pH-controlled drug loading and
release from biodegradable microcapsules. Nanomed 2008;
4(4):302-310.
37. Udaya Sankar Kadimi, Deepan Raja Balasubramanian,
Usha Rani Ganni, Manohar Balaraman, Venkateswaran
Govindarajulu. In vitro studies on liposomal amphotericin
B obtained by supercritical carbon dioxide–mediated
process. Nanomed 2007; 3(4):273-289.
38. Sagar M. Agnihotri, Pradeep R. Vavia. Diclofenac-loaded
biopolymeric nanosuspensions for ophthalmic application.
Nanomed 2009; 5(1):90-95.
39. Priya Prakash Karmali, Venkata Ramana Kotamraju, Mark
Kastantin, Matthew Black, Dimitris Missirlis, Matthew
Tirrell, Erkki Ruoslahti. Targeting of albumin-embedded
paclitaxel nanoparticles to tumors. Nanomed 2009;
5(1):73-82.
40. Raisuddin Ali, Gaurav K. Jain, Zeenat Iqbal, Sushma
Talegaonkar, Pragati Pandit, Sunita Sule, Geena Malhotra,
Roop K. Khar, Aseem Bhatnagar, Farhan J. Ahmad.
Development and clinical trial of nano-atropine sulfate dry
powder inhaler as a novel organophosphorous poisoning
antidote. Nanomed 2009 5(1):59-63.
41. Daniela Reischl, Andreas Zimmer. Drug delivery of
siRNA therapeutics: potentials and limits of nanosystems.
Nanomed 2009 5(1):8-20.
42. Hector Alvarez, Pamela Leal Rojas, Ken-Tye Yong, Hong
Ding, Gaixia Xu, Paras N. Prasad, Jean Wang, Marcia
Canto, James R. Eshleman, Elizabeth A. Montgomery,
Anirban Maitra. Mesothelin is a specific biomarker of
invasive cancer in the Barrett-associated adenocarcinoma
progression model: translational implications for diagnosis
and therapy. Nanomed 2008; 4(4):295-301.
43. Robert F. Service Policy: Priorities Needed for Nano-Risk
Research and Development. Science 2006; 314:5796.
44. Wei CM, Yih TC. Nanomedicine: Nanotechnology,
Biology, and Medicine 2005; 1:1.
45. Robert A and Freitas Jr. What is nanomedicine?
Nanomedicine: Nanotechnology Biology and Medicine
2005; 1:2– 9
46. Lajos P. Balogh.The future of nanomedicine and the future
of Nanomedicine: NBM. Nanomedicine: Nanotechnology
Biology and Medicine 2009;5:1.
47. Raj Bawa. NanoBiotech 2008: Exploring global advances
in nanomedicine. Nanomedicine: Nanotechnology Biology
and Medicine 2009; 5 :5–7.
49